ESC 365 - Combination therapy with GalNAc-siRNA drugs targeting both PCSK9 and APOC3 resulted in enhanced lipid lowering in mice

ESC Premium Access

Combination therapy with GalNAc-siRNA drugs targeting both PCSK9 and APOC3 resulted in enhanced lipid lowering in mice

Session: Lipids as cardiovascular risk factors and treatment options

Topic: Drug therapy

Speaker: Doctor J. Wikstrom (SE)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Doctor Johannes Wikstrom

(Sweden)

0 follower

4 more presentations in this session

Intraindividual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate-risk

Speaker: Doctor T. Harb (Baltimore, US)

Lipoprotein(a) metabolomic and proteomic features and atherosclerotic cardiovascular disease in young, asymptomatic adults

Speaker: Associate Professor S. Goonewardena (Ann Arbor, US)

Reduction of triglyceride-rich lipoproteins with retatrutide in type 2 diabetes may be explained by concurrent reduction in ANGPTL3/8 levels

Speaker: Doctor G. Ruotolo (Indianapolis, US)

Metabolomic profiling of the entire UK Biobank enables interpretation of familial hypercholesterolemia mutations and prediction of severe cardiovascular outcomes

Speaker: Doctor J. Barrett (Helsinki, FI)

Access the full session

Lipids as cardiovascular risk factors and treatment options

Speakers: Doctor J. Wikstrom, Doctor T. Harb, Associate Professor S. Goonewardena, Doctor G. Ruotolo, Doctor J. Barrett

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources